Sana Bio (SANA) Stock Forecast, Price Target & Predictions
SANA Stock Forecast
Sana Bio stock forecast is as follows: an average price target of $12.00 (represents a 168.46% upside from SANA’s last price of $4.47) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SANA Price Target
The average price target for Sana Bio (SANA) is $12.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 168.46% upside from SANA's last price of $4.47.
SANA Analyst Ratings
According to 3 Wall Street analysts, Sana Bio's rating consensus is 'Buy'. The analyst rating breakdown for SANA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Sana Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 16, 2024 | Emily Bodnar | H.C. Wainwright | $12.00 | $6.36 | 88.68% | 168.46% |
The latest Sana Bio stock forecast, released on Jan 16, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $12.00, which represents a 88.68% increase from the stock price at the time of the forecast ($6.36), and a 168.46% increase from SANA last price ($4.47).
Sana Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $4.47 | $4.47 | $4.47 |
| Upside/Downside | -100.00% | -100.00% | 168.46% |
In the current month, the average price target of Sana Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sana Bio's last price of $4.47. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 26, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Jan 16, 2024 | H.C. Wainwright | - | Buy | Upgrade |
Sana Bio's last stock rating was published by Citigroup on Aug 09, 2024. The company gave SANA a "Buy" rating, the same as its previous rate.
Sana Bio Financial Forecast
Sana Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Sana Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SANA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Sana Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict SANA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Sana Bio's previous annual EBITDA (undefined) of $NaN.
Sana Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-84.40M | $-84.40M | $-83.23M | $-78.54M | $-61.71M | $-65.64M | $-68.46M |
| High Forecast | $-84.40M | $-84.40M | $-83.23M | $-78.54M | $-61.71M | $-60.78M | $-68.46M |
| Low Forecast | $-84.40M | $-84.40M | $-83.23M | $-78.54M | $-61.71M | $-72.94M | $-68.46M |
| Surprise % | - | - | - | - | - | - | - |
Sana Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SANA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Sana Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Sana Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SANA last annual SG&A of $NaN (undefined).
Sana Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.36 | $-0.36 | $-0.35 | $-0.34 | $-0.26 | $-0.28 | $-0.29 |
| High Forecast | $-0.36 | $-0.36 | $-0.35 | $-0.34 | $-0.26 | $-0.26 | $-0.29 |
| Low Forecast | $-0.36 | $-0.36 | $-0.35 | $-0.34 | $-0.26 | $-0.31 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Sana Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SANA previous annual EPS of $NaN (undefined).
Sana Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| ZNTL | Zentalis Pharmaceuticals | $3.24 | $21.86 | 574.69% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| OLMA | Olema Pharmaceuticals | $12.70 | $27.00 | 112.60% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
SANA Forecast FAQ
Is Sana Bio a good buy?
Yes, according to 3 Wall Street analysts, Sana Bio (SANA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SANA's total ratings.
What is SANA's price target?
Sana Bio (SANA) average price target is $12 with a range of $12 to $12, implying a 168.46% from its last price of $4.47. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sana Bio stock go up soon?
According to Wall Street analysts' prediction for SANA stock, the company can go up by 168.46% (from the last price of $4.47 to the average price target of $12), up by 168.46% based on the highest stock price target, and up by 168.46% based on the lowest stock price target.
Can Sana Bio stock reach $7?
SANA's average twelve months analyst stock price target of $12 supports the claim that Sana Bio can reach $7 in the near future.
What are Sana Bio's analysts' financial forecasts?
Sana Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-196M (high $-191M, low $-203M), average SG&A $0 (high $0, low $0), and average EPS is $-0.835 (high $-0.815, low $-0.866). SANA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-331M (high $-331M, low $-331M), average SG&A $0 (high $0, low $0), and average EPS is $-1.41 (high $-1.41, low $-1.41).